摘要
目的:观察前列地尔脂微球载体注射液(Lipo-PGE1)对慢性乙型重型肝炎患者血清肿瘤坏死因子-α(TNF-α)的影响。方法:选择慢性乙型重型肝炎患者60例,随机分为试验组(n=30)及对照组(n=30),对照组用综合疗法,试验组在对照组治疗基础上加用Lipo-PGE110μg加入250mL葡萄糖溶液静滴,qd,疗程4周。观察治疗前后血清TNF-α的变化。结果:试验组治疗后血清TNF-α水平为(164.47±10.89)pg·mL-1与治疗前(375.44±12.15)pg·mL-1相比显著下降(P<0.001);对照组治疗后血清TNF-α水平(263.39±10.85)pg·mL-1,与试验组比较差异有显著性(P<0.001)。结论:Lipo-PGE1注射液可降低慢性乙型重型肝炎患者血清TNF-α的水平,是其治疗慢性重型肝炎的作用机制之一。
Objective：To assess the effects of lipo-PGE1 injection on serum TNF-α in patients with chronic severe hepatitis B. Methods：60 patients with chronic severe hepatitis B were randomized 1 ： 1 to one of two treatment arms, conventional therapy, or lipo-PGE1 injection （ 10 μg in 250 mL glucose solution, qd ） plus conventional therapy for 4 weeks. The serum TNF-α level was monitored prior to and post the therapy. Results：The serum TNF-α level post lipo-PGE1 was significantly decreased compared to the ones prior to lipo-PGE1 [ （164.47 ± 10.89） vs. （375.44 ± 12.15） pg·mL^-1, P 〈 0.001 ]. The patients in the conventional therapy alone had the serum TNF-α level of（263.39 ± 10.85）pg·mL^-1 post the therapy, which was significantly higher than the lipo-PGE1 patients（ P 〈 0.001 ）. Conclusion： Lipo-PGE1 injection treats chronic severe hepatitis B by reducing the serum TNF-αlevel.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2005年第8期1057-1058,共2页
Chinese Journal of New Drugs
